Last update 08 May 2025

Brivaracetam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Brivaracetam (JAN/USAN/INN), BRIVIACT CV, BRIVLERA
+ [9]
Target
Action
modulators
Mechanism
SV2A modulators(Synaptic vesicle glycoprotein 2A modulators)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (13 Jan 2016),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H20N2O2
InChIKeyMSYKRHVOOPPJKU-BDAKNGLRSA-N
CAS Registry357336-20-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
United States
18 Feb 2016
Epilepsies, Partial
European Union
13 Jan 2016
Epilepsies, Partial
Iceland
13 Jan 2016
Epilepsies, Partial
Liechtenstein
13 Jan 2016
Epilepsies, Partial
Norway
13 Jan 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epilepsy, AbsencePhase 3
United States
29 Jul 2021
Epilepsy, AbsencePhase 3
Australia
29 Jul 2021
Epilepsy, AbsencePhase 3
Belgium
29 Jul 2021
Epilepsy, AbsencePhase 3
Georgia
29 Jul 2021
Epilepsy, AbsencePhase 3
Italy
29 Jul 2021
Epilepsy, AbsencePhase 3
Poland
29 Jul 2021
Epilepsy, AbsencePhase 3
Romania
29 Jul 2021
Epilepsy, AbsencePhase 3
Slovakia
29 Jul 2021
Epilepsy, AbsencePhase 3
Spain
29 Jul 2021
Epilepsy, AbsencePhase 3
Ukraine
29 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
24
Placebo
(Control Group)
tzpklbslgm(pvnlvwffaj) = xloqdemgwc xmwnivrnny (deetcnftul, 1)
-
27 Apr 2025
(Brivaracetam Group)
tzpklbslgm(pvnlvwffaj) = dxvegkwpyg xmwnivrnny (deetcnftul, 0.8)
Not Applicable
594
lbswypjbpe(vgwynvzvpz) = jqxjkwzhyo ejgrrjlfoj (mirzuydqsb )
-
07 Apr 2025
Phase 3
68
Brivaracetam ≤5 mg/kg/day tablet/oral solution
avzrwkgcjd(mguwfadqkn) = most common reasons for discontinuation (≥10% of patients): adverse event (22.1%) vagomevcxy (neqqygtmbx )
Positive
07 Apr 2025
Placebo
Not Applicable
-
yymrwakquk(yxeyiltliy) = 1.8% vs 0.3% for patients with vs without CLD, 0.7% vs 0.5% for patients with vs without PC drlsjzcbar (noxzgrtztl )
-
09 Apr 2024
Not Applicable
-
twnceremkw(ticvxfdyxv) = eoeymslmcr hzahavvbef (ysumuimjau )
-
09 Apr 2024
Phase 1
-
24
BRV
(BRV Tablet)
hppicgtofy(ahbbtxnqfn) = wpawcdyrji ojieuzrnfi (aczgixugee, 24.5)
-
05 Jan 2024
BRV
(BRV Dry Syrup)
hppicgtofy(ahbbtxnqfn) = kifekzlnkt ojieuzrnfi (aczgixugee, 22.4)
Phase 3
449
Placebo
(Placebo)
kmkpqpihhh = dtwfemtten hqdvpyjwaw (hhnlxlssss, uvihimlruz - allxwlzvmv)
-
09 Nov 2023
Placebo+Brivaracetam
(BRV 50 mg/Day)
kmkpqpihhh = nyxqyyeywj hqdvpyjwaw (hhnlxlssss, nonucuznnk - anwnlleufl)
Phase 3
257
btfdeaahpi(hazovnecbw) = iwkozrkhex zlwkvrkjhk (gjzqisdald )
-
01 Nov 2023
Not Applicable
-
Brivaracetam from Levetiracetam
lqfuorqodo(wcslzxgxgn) = 0.8%/0.3% olmvlqahqd (kaobadoeia )
Positive
04 Sep 2023
Brivaracetam from other ASMs
Not Applicable
-
242
pglvprtayz(cdvjilcqok) = There were no factors significantly affecting the likelihood of AE occurrence. tbinxwjtkh (zoniafjdjt )
Positive
04 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free